06/15 Taiwan BIO Weekly
2026-06-15 |
| Taiwan BIO Weekly |
| GlycoNex's Denosumab biosimilar SPD8 reports positive progress, aims for launch next year 12 June, 2026 GlycoNex (TW: 4168) announced on the 11th of June that its Denosumab biosimilar SPD8 for osteoporosis, co-developed with Japan's Mitsubishi Gas Chemical (MGC), has successfully completed unblinding of its Phase III clinical trial. The study met its pre-defined equivalence criteria for the primary efficacy endpoint, marking a key milestone toward regulatory submission. More... (in Chinese) |
| OBI Pharma's ADC technology showcased at World ADC Summit South Korea 11 June, 2026 OBI Pharma (TW: 4174) announced that it was invited to the 5th World ADC Summit South Korea, held in Seoul, 9-11 June, and delivered three keynote presentations showcasing the latest developments from its Obrion antibody-drug conjugate (ADC) technology platform. The presentations covered its GlycOBIR glyco-conjugation technology, the GlycOBI DUOR dual-payload ADC platform, and next-generation ADC analytics and process development technologies, further enhancing the company's international visibility. More... (in Chinese) |
| Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health Press release 11 June, 2026 Backed by International Authority -- Caliway's (TW: 6919) latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP-1R-based weight-loss therapies, were presented at the American Diabetes Association 2026 Scientific Sessions (ADA 2026). The findings were delivered by Timothy Garvey, MD, an internationally renowned expert in obesity and metabolic medicine and a scientific advisor to Caliway, garnering significant interest from global experts and multinational pharmaceutical companies. More... |
| Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery Press release 11 June, 2026 Taiwan-based Formosa Pharmaceuticals (TW: 6838) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in Vietnam. Samil, established in 1947, is one of the most prominent Korean manufacturers of pharmaceutical products across multiple therapeutic areas, with a core specialization and focus on ophthalmic medicines, and having long-standing partnerships with global players such as Samsung, Abbvie, Nicox, and Thea. The licensing agreement includes upfront payment, regulatory milestones, and royalties, throughout the term of the agreement. More... |
| EirGenix May revenue climbs 56%, supported by CDMO growth 10 June, 2026 EirGenix (TW: 6589) reported May revenue of NT$116 million, up 56.35% year-over-year and 42.08% month-over-month, bringing cumulative revenue for the first five months of 2026 to NT$507 million, a 43.25% increase from a year earlier. The growth was driven by licensing revenue from its breast cancer biosimilar EG1206A, the transfer of existing CDMO projects to its Zhubei facility, and the progression of new projects into late-stage technology transfer and GMP manufacturing preparation. The company expects these developments to continue supporting strong revenue growth in the second half of 2026. More... (in Chinese) |
| Medimaging Integrated Solution partners with iPass to expand precision orthopedic minimally invasive market 10 June, 2026 Medimaging Integrated Solution (TW: 6796) announced that its disposable sterile single-use electronic arthroscope EJA100, which has been approved for market launch by Taiwan s TFDA, will be exclusively licensed to orthopedic trauma and corrective medical devices company A Plus Biotechnology (TW: 6918). The two companies will combine Medimaging's R&D and manufacturing capabilities in disposable digital endoscopy with A Plus Biotechnology s clinical expertise and orthopedic distribution network to jointly expand Taiwan's precision minimally invasive orthopedic treatment market. More... (in Chinese) |
| Novartis and Taiwan Advance a New ASCVD Framework 10 June, 2026 Cardiovascular disease remains one of Taiwan's leading public health challenges, with atherosclerotic cardiovascular disease (ASCVD) -- a condition caused by plaque buildup in the arteries -- accounting for a significant share of morbidity and mortality. More... |
| Novo Nordisk Taiwan and the Shift From Weight Loss to Long-Term Health 10 June, 2026 In a society where more than half of adults are overweight or obese, obesity is more widely understood not simply as a lifestyle issue for Taiwanese, but as a chronic disease with implications for public health, healthcare sustainability, and workforce productivity. More... |
| PharmaEssentia Announces Taiwan Approval of BESREMi for Essential Thrombocythemia, Marking First Global Approval in ET Press release 10 June, 2026 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TW: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the Taiwan's Ministry of Health and Welfare (MOHW) has approved ropeg interferon alfa-2b-njft (BESREMi ) for the treatment of adult patients with essential thrombocythemia (ET). BESREMi is the first new therapy approved for ET in nearly 30 years. More... |
| Johnson & Johnson Connects Innovation to Patient Access for a Healthier Taiwan Interview 10 June, 2026 Taiwan s "Healthy Taiwan" initiative sets out a vision for healthcare transformation, centered on prevention, earlier diagnosis, digitalization, and more sustainable long-term care. For Johnson & Johnson Taiwan, the significance of that vision lies in expanding access to innovation and in redesigning how patients move through care itself. More... |
| Moderna in Taiwan: Building an mRNA Innovation Ecosystem Interview 10 June, 2026 As Taiwan strengthens its leadership in healthcare innovation, Moderna is deepening its commitment -- advancing mRNA science, partnerships, and long-term capabilities that help shape the future of medicine. More... |
| Taiwan establishes APEC's first dedicated healthcare sub-fund 9 June, 2026 Taiwan established the Asia-Pacific Economic Cooperation Sub-Fund for the Future of Healthcare, the forum's first such dedicated fund, highlighting government commitment to leveraging the country s smart medical care strengths to reinforce Taiwan's leading role in APEC's discussions of digital healthcare while providing more business opportunities for domestic industries. More... |
| Gongwin Biopharm's liver cancer drug advances into Phase III clinical trials 8 June, 2026 Gongwin Biopharm (TW: 6617) announced that enrollment has been completed in the Taiwan Phase II clinical trial of its liver cancer therapy PTS100 for patients with unresectable or otherwise difficult-to-treat hepatocellular carcinoma (HCC). The randomized, open-label study is now moving into the efficacy evaluation stage at five major Taiwanese medical centers, including National Taiwan University Hospital and Taipei Veterans General Hospital. Building on this milestone, the company plans to launch a multinational, multicenter Phase III trial in the third quarter of 2026 across Taiwan, Japan, Thailand, and the US, while also conducting an investigator-initiated trial (IIT) in China to support the expansion of the drug's indications. More... (in Chinese) |
| HanchorBio's anticancer drug shows progress in clinical trials 8 June, 2026 HanchorBio (TW: 7827) said its core anticancer drug HCB101 continues to make progress in clinical development. The drug is currently undergoing a multinational Phase Ib/IIa trial, with encouraging efficacy signals observed in indications including gastric cancer and triple-negative breast cancer, according to the company. HCB101 is the first product derived from HanchorBio s proprietary FBDB multifunctional fusion protein platform and is positioned as a best-in-class CD47-targeting anticancer therapy. The drug is primarily being developed in combination regimens, including with ramucirumab and paclitaxel, to expand its use across gastric cancer, head and neck cancer, colorectal cancer, and triple-negative breast cancer. More... (in Chinese) |
| Sunhawk Vision Biotech touts RNA eye therapy SHJ002 8 June, 2026 Sunhawk Vision Biotech (TW: 7759) said on the 8th of June that its innovative eye drop SHJ002, developed using microRNA technology supported by Nobel Prize-winning theoretical research, is becoming a focal point of attention for major international pharmaceutical companies. The company noted that global interest in RNA therapeutics has reached an unprecedented level in recent years, and multinational pharmaceutical firms such as Novartis and Novo Nordisk have invested hundreds of millions to billions of dollars in acquiring microRNA-related drug development companies. More... (in Chinese) |
| BRIM Biotechnology eye drug completes Phase II enrollment 8 June, 2026 BRIM Biotechnology (TW: 6885), which focuses on ophthalmic drug development, said on 8th of June that its investigational drug BRM424 for neurotrophic keratitis is currently undergoing a Phase II clinical trial in the United States and Brazil. The trial is designed to enroll 14 participants, and the final subject expected to be enrolled by the end of June. Preliminary results from this open-label study indicate that most patients have shown significant symptom improvement. Notably, BRM424 demonstrates a unique advantage in rapidly restoring corneal nerve sensitivity in affected patients. More... (in Chinese) |
| HuniLife Biotechnology's immuno-targeted cancer drug studies published in three international journals 8 June, 2026 HuniLife Biotechnology announced that its self-developed immuno-targeted anticancer drug HuL001 has initiated a clinical trial for multiple myeloma in Taiwan. At the same time, preclinical studies on HuL001's mechanism of action have recently been published in a series of international journals, including Cell Death & Disease, Cancers, and Oncology Research. These publications provide scientific support for its clinical development and suggest that HuL001 may have potential applications across multiple cancer types. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |